Screening of potential regulatory genes in carotid atherosclerosis vascular immune microenvironment Authors: Yi Zhang, Lingmin Zhang, Yunfang Jia, Jing Fang, Shuancheng Zhang, Xianming Hou, Misbahuddin Rafeeq, Misbahuddin Rafeeq, Misbahuddin Rafeeq, Misbahuddin Rafeeq Published: 2024 ABSTRACT BackgroundImmune microenvironment is one of the essential characteristics of carotid atherosclerosis (CAS), which cannot be reversed by drug therapy alone. Thus, there is a pressing need to develop novel immunoregulatory strategies to delay this pathological process that drives cardiovascular-related diseases. This study aimed to detect changes in the immune microenvironment of vascular tissues at various stages of carotid atherosclerosis, as well as cluster and stratify vascular tissue samples based on the infiltration levels of immune cell subtypes to distinguish immune phenotypes and identify potential hub genes regulating the immune microenvironment of carotid atherosclerosis.Materials and methodsRNA sequencing datasets for CAS vascular tissue and healthy vascular tissue (GSE43292 and GSE28829) were downloaded from the Gene Expression Omnibus (GEO) database. To begin, the immune cell subtype infiltration level of all samples in both GSE43292 and GSE28829 cohorts was assessed using the ssGSEA algorithm. Following this, consensus clustering was performed to stratify CAS samples into different clusters. Finally, hub genes were identified using the maximum neighborhood component algorithm based on the construction of interaction networks, and their diagnostic efficiency was evaluated.ResultsCompared to the controls, a higher number of immune cell subtypes were enriched in CAS samples with higher immune scores in the GSE43292 cohort. Advanced CAS was characterized by high immune cell infiltration, whereas early CAS was characterized by low immune cell infiltration in the GSE28829 cohort. Moreover, CAS progression may be related to the immune response pathway. Biological processes associated with muscle cell development may impede the progression of CAS. Finally, the hub genes PTPRC, ACTN2, ACTC1, LDB3, MYOZ2, and TPM2 had satisfactory efficacy in the diagnosis and prediction of high and low immune cell infiltration in CAS and distinguishing between early and advanced CAS samples.ConclusionThe enrichment of immune cells in vascular tissues is a primary factor driving pathological changes in CAS. Additionally, CAS progression may be related to the immune response pathway. Biological processes linked to muscle cell development may delay the progression of CAS. PTPRC, ACTN2, ACTC1, LDB3, MYOZ2, and TPM2 may regulate the immune microenvironment of CAS and participate in the occurrence and progression of the disease. Introduction As is well documented, carotid atherosclerosis (CAS), the pathological basis of carotid artery stenosis, is prevalent in middle-aged and elderly individuals [1]. According to a recent epidemiological survey, up to 12% of elderly men and 5% of women suffer from asymptomatic moderate atherosclerotic neck vessel stenosis, while severe carotid artery stenosis accounted for 3% and 1% of elderly men and women, respectively [2, 3]. Indeed, it has emerged as one of the leading causes of accidental death among the elderly population worldwide [4]. The carotid artery is frequently affected by atherosclerosis and is a major contributor to ischemic stroke [5–7]. The risk of cerebral ischemia in patients with carotid atherosclerosis depends on the degree of carotid artery stenosis [8–10]. The pathological basis of atherosclerosis chiefly involves lipid deposition under the intima of the middle great artery [11–13]. The immune response exerts a significant effect on the development of carotid atherosclerosis at all stages [14, 15]. A large number of immune factors were detected in carotid atherosclerotic lesions, including immune cells and their cytokines. Pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-12, may accelerate the progression of carotid atherosclerosis [16–19]. Conversely, anti-inflammatory cytokines such as IL-10, TGF-β, and Arg-1 may delay the development of carotid atherosclerosis [20, 21]. Immune microenvironment is one of the essential characteristics of carotid atherosclerosis. Given that carotid atherosclerosis cannot be reversed by drug therapy alone, there is an urgent need to formulate new immunoregulatory strategies to prevent this pathological process that causes cardiovascular-related diseases. Therefore, this study aimed to detect changes in the immune microenvironment of vascular tissues at different stages of carotid atherosclerosis, as well as cluster and stratify vascular tissue samples based on the infiltration levels of immune cell subtypes to distinguish between different immune phenotypes and identify potential hub genes regulating the immune microenvironment of carotid atherosclerosis. Materials and methods Data download RNA sequencing datasets for CAS vascular tissue and healthy vascular tissue (GSE43292 [22] and GSE28829 [23]) were retrieved from the Gene Expression Omnibus (GEO) database. Thirty-two CAS samples in the GSE43292 cohort were regarded as the CAS group, and paired 32 normal vascular tissue samples were designated as the control group. In the GSE28829 cohort, 13 early CAS samples and 16 advanced CAS samples were categorized as the early and advanced CAS groups. Quantification of immune microenvironment The ssGSEA algorithm was used to convert RNA sequencing data from all samples to immune cell subtype infiltration data. Then, the immune scores of all samples were calculated using the ESTIMATE algorithm. Consensus cluster Ward’s method was utilized for consensus clustering to divide CAS samples in the GSE43292 cohort. When K = x (when the samples were divided into x clusters), the cumulative distribution function was the flattest in the range of consensus index values ([0.1, 0.9]). Differentially expressed genes (DEGs) DEGs were identified using the following criteria: genes with a logarithm of fold change exceeding 1 and an adjusted P value less than 0.05. Enrichment analysis With human genes as the background, enrichment analysis of DEGs was conducted using R package (clusterProfiler) based on gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) databases. KEGG pathways and GO terms were retained based on a screening condition of q < 0. 05. Hub gene screening Protein-protein interaction networks (PPI) of DEGs were generated using the STRING website (http://string-db.org). The CytoHubba plug-in of Cytoscape 3.2 software and the maximum neighborhood component algorithm were employed to screen hub genes among DEGs. The top 10 genes were retained. Principal component analysis (PCA) A linear function that converted original variables to new variables and removed redundant information was constructed. Principal component 1 and principal component 2 were used to construct a two-dimensional plane to characterize the phenotype of the samples. Statistical analysis Correlation analysis was conducted using the Spearman test. The receiver operator characteristic curve (ROC) was plotted to evaluate the diagnostic value of DEGs. Considering that the datasets used are publicly available, the requirement for ethics committee review was waived. Ethical approval All data in this study are publicly available and did not require ethics committee review. Results Changes in the immune microenvironment in CAS With the exception of Type 2 T helper cells, central memory CD8 T cells, central memory CD4 T cells, and effector memory CD8 T cells, the levels of infiltration of the majority of immune cell subtypes were higher in the CAS samples compared to the control samples in the GSE43292 cohort (P < 0.001, Fig 1A). Likewise, the immune score in CAS samples was higher than that in control samples in the GSE43292 cohort (P < 0.001, Fig 1B). In the GSE43292 cohort, PCA based on immune cell subtype infiltration showed that CAS and control samples were clustered in different regions in the coordinate system composed of principal component 1 as the X-axis and principal component 2 as the Y-axis (Fig 1C). Overall, these results exposed that control and CAS samples possessed different immune microenvironment characteristics, which may play a decisive role in disease development and could be used to differentiate between control and CAS samples. Difference in the immune microenvironment between CAS and control samples in the GSE43292 cohort. (A) Differences in immune cell subtypes between CAS and control samples. (B) Differences in immune scores between CAS and control samples. (C) Principal component analysis based on the infiltration level of immune cell subtypes in CAS and control samples. Abbreviation: CAS, carotid atherosclerosis; PC, principal component. Similarly, the infiltration levels of the majority of immune cell subtypes were higher in the advanced CAS samples than in the early CAS samples in the GSE28829 cohort (Fig 2A). As anticipated, the immune score of advanced CAS samples was higher than that of early CAS samples in the GSE43292 cohort (P < 0.001, Fig 2B). Additionally, PCA based on immune cell subtype infiltration demonstrated that advanced and early CAS samples were clustered in different regions in the coordinate system composed of principal component 1 as the X-axis and principal component 2 as the Y-axis (Fig 2C). The immune microenvironment is a key hallmark of disease and changes throughout the disease process. Describing the phenotypes of diseases based on the immune microenvironment can delineate the heterogeneity of CAS and offer new insights into its pathogenesis. Differences in the immune microenvironment between early and advanced carotid atherosclerosis samples in the GSE28829 cohort. (A) Differences in immune cell subtypes between early and advanced CAS samples. (B) Differences in immune scores between early and advanced CAS samples. (C) Principal component analysis based on the infiltration level of immune cell subtypes in early and advanced CAS samples. Abbreviation: CAS, carotid atherosclerosis; PC, principal component. Consensus clustering of the CAS samples To further elucidate the characteristics of the immune microenvironment in CAS samples and explore the underlying mechanism, consensus clustering was carried out on CAS samples in the GSE43292 cohort. When K = 2 (samples were divided into two clusters), the cumulative distribution function exhibited optimal flatness in the range of consensus index values ([0.1, 0.9], Fig 3A). Next, CAS samples in the GSE43292 cohort were divided into 2 clusters, with cluster A comprising 19 samples and cluster B consisting of 13 samples (Fig 3B). The infiltration levels of most immune cell subtypes, with the exception of Type 2 T helper cells, central memory CD8 T cells, central memory CD4 T cells, and effector memory CD8 T cells, were significantly higher in Cluster A, followed by cluster B and control samples, respectively (P < 0.001, Fig 3C). Similarly, the immune score in cluster A was significantly higher compared to cluster B and the control samples (P < 0.001, Fig 3D). PCA based on immune cell subtype infiltration uncovered that cluster A and cluster B samples were clustered in different regions of the coordinate system composed of principal component 1 as the X-axis and principal component 2 as the Y-axis (Fig 3E). Cluster A was characterized by high immune cell infiltration levels, whereas Cluster B was characterized by low immune cell infiltration levels. High and low immune infiltration subtypes of CAS samples in the GSE43292 cohort distinguished via consensus clustering. (A) Cumulative distribution function curve for different K values. (B) Consensus matrix when K = 2. CAS samples were divided into cluster A and cluster B. (C) Differences in the infiltration level of immune cell subtypes between cluster A, cluster B, and the control group. (D) Differences in the infiltration level of immune cell subtypes between cluster A, cluster B, and the control group. (E) Principal component analysis based on the infiltration level of immune cell subtypes in cluster A and cluster B CAS samples. Abbreviation: CDF, cumulative distribution function; PC, principal component. Note: ***, P < 0.001; **, P < 0.01; ns, P > 0.05. Enrichment analysis and hub gene screening Compared to the control group, immune-related KEGG pathway gene sets, such as Toll-like receptor signaling pathways, antigen processing and presentation, and intestinal immune network for IgA production, were enriched in cluster B of the GSE43292 cohort (Fig 4A). On the other hand, immune-related KEGG pathway genes, such as antigen processing and presentation, were enriched in cluster A (Fig 4B). To further explore the enrichment mechanism of immune cells in CAS samples, DEGs in Cluster A and control samples of the GSE43292 cohort were investigated. Up-regulated DEGs in cluster A of the GSE43292 cohort were enriched in biological processes related to the activation of immune response, leukocyte migration, and leukocyte activation involved in immune response (Fig 5A). They were also enriched in cellular components such as the secretory granule membrane, external side of the plasma membrane, and tertiary granule (Fig 5A), as well as in molecular functions such as immune receptor activity (Fig 5A). Finally, they were enriched in KEGG pathways related to the immune response (Fig 5B). Conversely, up-regulated DEGs in the control group of the GSE43292 cohort were enriched in biological processes such as muscle system process, muscle contraction, and muscle tissue development (Fig 5C), in cellular components associated with contractile fiber, myofibril, and sarcomere (Fig 5C), and in molecular functions involving the structural constituent of muscle (Fig 5C). Notably, they were also enriched in KEGG pathways involving dilated cardiomyopathy, hypertrophic cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy (Fig 5D). Afterward, PPI networks were constructed based on the up-regulated and down-regulated genes of cluster A compared to the control samples. The PPI data of both up-regulated and down-regulated gene sets were imported into Cytoscape software, following which the maximum neighborhood algorithm was applied to identify the top 10 hub genes with the strongest interactions. The highest-ranking hub gene in the PPI network of the up-regulated gene set in cluster A was PTPRC (Fig 5E), while that of the down-regulated gene set was ACTN2 (Fig 5F). Interestingly, the relationship between ACTC1, LDB3, MYOZ2, TPM2, and CAS has not been described in previous literature. Gene set variation analysis (GSVA) between cluster A, cluster B, and the control group. (A) GSVA between cluster B and the control group. (B) GSVA between cluster A and the control group. Enrichment analysis and hub gene screening. (A) GO enrichment analysis of up-regulated genes in cluster A compared to the control group. (B) KEGG enrichment analysis of up-regulated genes in cluster A compared to the control group. (C) GO enrichment analysis of down-regulated genes in cluster A compared to the control group. (D) KEGG enrichment analysis of down-regulated genes in cluster A compared to the control group. (E) Hub gene interaction network of up-regulated genes in cluster A compared to the control group. Red to yellow indicates that genes rank from high to low in the interaction network, with PTPRC being the highest-ranking gene identified via the maximum neighborhood component algorithm. (F) Hub gene interaction network of down-regulated genes in cluster A compared to the control group. Red to yellow indicates that genes rank from high to low in the interaction network, with ACTN2 being the highest-ranking gene identified via the maximum neighborhood component algorithm. Abbreviation: BP, Biological Process; CC, Cellular Component; MF, molecular function. Diagnostic efficacy of hub genes The expression level of PTPRC was higher in the cluster A samples compared to the cluster B and control samples (Fig 6A), whereas that of ACTN2 was lower (Fig 6B). The area under the ROC curve of ACTN2 and PTPRC was 0.844 and 0.787 for distinguishing between CAS and control samples, respectively (Fig 6C and 6D). Moreover, the area under the ROC curve of ACTN2 and PTPRC was 0.986 and 0.939 for distinguishing between cluster A and cluster B, respectively (Fig 6E and 6F). The expression level of PTPRC was higher in advanced CAS samples compared to early CAS samples (Fig 7A). In contrast, the expression level of ACTN2 was lower in advanced CAS samples compared with early CAS samples (Fig 7B). The area under the ROC curve of ACTN2 and PTPRC was 0.913 and 0.909 for differentiating between advanced CAS samples and early CAS samples, respectively (Fig 7C and 7D). In CAS samples of the GSE43292 and GSE28829 cohorts, ACTN2 expression was negatively correlated with the infiltration level of most immune cell subtypes (Fig 8A and 8B), whereas PTPRC expression was positively correlated with the infiltration level of most immune cell subtypes (Fig 8A and 8B). Notably, the expression levels of ACTC1, LDB3, MYOZ2, and TPM2 were lower in cluster A samples compared with cluster B and control samples (Fig 9A–9D). The area under the ROC curve of ACTC1, LDB3, MYOZ2, and TPM2 for distinguishing CAS samples from control samples was 0.790, 0.807, 0.831, and 0.834, respectively (Fig 9E–9H). The area under the ROC curve of ACTC1, LDB3, MYOZ2, and TPM2 for distinguishing between cluster A and cluster B was 0.927, 0.988, 0.960 and 0.992, respectively (Fig 9I–9L). Of note, the expression levels of ACTC1 (Fig 10A), MYOZ2 (Fig 10C), and TPM2 (Fig 10D) were lower in advanced CAS samples compared with early CAS samples. However, LDB3 expression was comparable between advanced and early CAS samples (Fig 10B). The area under the ROC curve of ACTC1, LDB3, MYOZ2, and TPM2 for differentiating advanced CAS samples from early CAS samples was 0.721, 0.683, 0.764, and 0.865, respectively (Fig 10E–10H). In the CAS samples of the GSE43292 (Fig 11A) and GSE28829 cohorts (Fig 11B), the expression of ACTC1, LDB3, MYOZ2, and TPM2 was negatively correlated with infiltration levels of most immune cell subtypes. Diagnostic efficiency evaluation of PTPRC and ACTN2 in the GSE43292 cohort. (A and B) Differences in PTPRC and ACTN2 expression between cluster A, cluster B, and the control group. (C and D) ACTN2 and PTPRC diagnostic efficiency on distinguishing the carotid atherosclerosis and control samples. (E and F) The accuracy of ACTN2 and PTPRC in distinguishing cluster A and cluster B samples. Abbreviation: CAS, carotid atherosclerosis; PC, principal component; AUC, area under curve; CI, confidence interval. Note: ***, P < 0.001; *, P < 0.05; ns, P > 0.05. Diagnostic efficiency validation of PTPRC and ACTN2 in the GSE28829 cohort. (A and B) Difference in PTPRC and ACTN2 expression between advanced and early CAS samples. (C and D) The accuracy of ACTN2 and PTPRC for distinguishing between advanced and early CAS samples. Abbreviation: CAS, carotid atherosclerosis; PC, principal component; AUC, area under curve; CI, confidence interval. Note: ***, P < 0.001; *, P < 0.05; ns, P > 0.05. Correlation between PTPRC, ACTN2, and immune cell subtypes. (A) Correlation between PTPRC, ACTN2, and immune cell subtypes in CAS samples in the GSE43292 cohort. (B) Correlation between PTPRC, ACTN2, and immune cell subtypes in CAS samples in the GSE28829 cohort. Note: ***, P < 0.001; **, P < 0.01; *, P < 0.05. Diagnostic efficiency evaluation of hub genes in the GSE43292 cohort. (A-D) Differences in ACTC1, LDB3, MYOZ2, and TPM2 expression between cluster A, cluster B, and the control group. (E-H) The accuracy of ACTC1, LDB3, MYOZ2, and TPM2 for distinguishing between CAS and control samples. (I-L) The accuracy of ACTC1, LDB3, MYOZ2, and TPM2 for distinguishing between cluster A and cluster B samples. Abbreviation: CAS, carotid atherosclerosis; AUC, the area under the curve; CI, confidence interval. Note: ***, P < 0.001; *, P < 0.05; ns, P > 0.05. Diagnostic efficiency validation of ACTC1, LDB3, MYOZ2, and TPM2 in the GSE28829 cohort. (A-D) Differences in ACTC1, LDB3, MYOZ2, and TPM2 expression between advanced and early CAS samples. (E-H) The accuracy of ACTC1, LDB3, MYOZ2, and TPM2 for distinguishing advanced from early CAS samples. Abbreviation: CAS, carotid atherosclerosis; AUC, the area under the curve; CI, confidence interval. Note: ***, P < 0.001; *, P < 0.05; ns, P > 0.05. Correlations between ACTC1, LDB3, MYOZ2, TPM2, and immune cell subtypes. (A) Correlation between ACTC1, LDB3, MYOZ2, TPM2, and immune cell subtypes in CAS samples in the GSE43292 cohort. (B) Correlation between ACTC1, LDB3, MYOZ2, TPM2, and immune cell subtypes in CAS samples in the GSE28829 cohort. Note: ***, P < 0.001; **, P < 0.01; *, P < 0.05. Discussion At present, advances in microarray have facilitated the comprehensive analysis of mRNA expression profiles across the global genome. The GSE43292 dataset contained the RNA sequencing data of CAS vascular tissue and adjacent healthy vascular tissue pairs, whilst the GSE28829 comprised early and advanced CAS vascular tissue. These two sets of samples, including control vascular tissue, early diseased vascular tissue, and advanced diseased vascular tissue, enabled the characterization of changes in the immune microenvironment throughout disease progression to determine trends and statuses of the immune microenvironment during pathological transformation associated with the disease. The results of this study unveiled that compared with healthy vascular tissue, immune cells were enriched in CSA samples throughout disease progression. Specifically, the level of immune cell infiltration was higher in advanced CAS samples compared to early CAS samples. Previous studies reported that various immune cell subtypes play a pivotal role in the pathogenesis of CAS [24–26]. Macrophages drive atherosclerosis and associated complications, playing distinct roles across all stages of atherosclerosis, and are also the most abundant type of inflammatory cells in plaques [27]. In addition to the high level of infiltration of macrophages, their plasticity and heterogeneity play a vital role in the immune response to atherosclerosis [28]. Indeed, macrophages can shift their phenotype according to their microenvironment to allow them to fulfill specific roles [28, 29]. For instance, M1 macrophages promote and maintain inflammatory responses and thus exert atherogenic effects [30]. In contrast, type 2 T helper cells stimulate the differentiation of M2 macrophages [31, 32], which express high levels of anti-inflammatory factors, balance the activity of M1 macrophages, alleviate inflammatory responses, initiate tissue repair, promote tissue remodeling and angiogenesis, and exert phagocytic effects to mediate the inflammatory response, thereby exerting anti-atherosclerotic effects [33, 34]. Herein, the level of type 2 T helper cells remained unchanged in both early and advanced CAS samples. Dendritic cells play an essential role in CAS by stimulating chemokine and cytokine secretion and participating in antigen presentation and lipid uptake, which may induce inflammation or promote immune tolerance [35–37]. B cells may be implicated in systemic and local immune responses to atherosclerosis by modulating cellular immune responses through intercellular contact, antigen presentation, and cytokine production [38, 39]. T cells are the second largest group of immune cells in carotid atherosclerotic plaques after macrophages. Th1 cells were the dominant form in atherosclerotic plaques, forming a mutually stimulating loop with macrophages conducing to disease progression [40, 41]. Furthermore, PCA demonstrated that the level of immune cell infiltration could be used to distinguish healthy vascular tissue from CAS samples, both early and late stages. The immune microenvironment is one of the essential characteristics of disease and can be used to describe different disease phenotypes. The enrichment of immune cells in vascular tissues was identified as a principal driving force behind pathological changes in diseases. Characterizing the immune microenvironment characteristics of CAS samples and exploring the enrichment mechanism of immune cell subtypes in CAS samples may potentially assist in elucidating disease heterogeneity and the molecular mechanism underlying disease progression. Hub genes that regulate the immune microenvironment or are significantly associated with the infiltration of immune cell subtypes may be potential diagnostic markers and therapeutic targets. To delineate the heterogeneity of CAS samples and identify the enrichment mechanism of immune cells, CAS samples were divided into cluster A, hallmarked by a high infiltration level of immune cell subtypes, and cluster B, featuring a low infiltration level of immune cell subtypes via consensus clustering. In order to detect changes in the immune microenvironment, differentially expressed genes were identified between high immune infiltration clusters and healthy vascular tissues. Importantly, up-regulated genes in cluster A were significantly enriched in biological processes related to immune response, whereas down-regulated genes were significantly enriched in biological processes related to muscle development. The pathogenesis of atherosclerotic lesions has been hypothesized to be an exaggerated response to damage of endothelial cells and smooth muscle cells in the arterial wall [42, 43]. According to prior investigations, smooth muscle cell proliferation, smooth muscle cell synthesis, and secretion of connective tissue components are the critical pathological changes observed in atherosclerosis [44, 45]. The results of the enrichment analysis validated the representativeness of the selected DEGs and the accuracy of sample classification. To identify hub genes that regulate or are significantly associated with the immune microenvironment, PPI networks were generated, and the MNC algorithm was applied to identify the highest-ranking hub genes, namely PTPRC and ACTN2. These genes were effective in disease diagnosis and differentiation between early and advanced stages of the disease. Specifically, PTPRC expression was positively correlated with most immune cell subtypes, with its expression level increasing with disease progression, implying that it promoted the development of the disease. In comparison, ACTN2 expression was negatively correlated with most immune cell subtypes, and its expression level decreased with disease progression, suggesting that it impeded disease progression. PTPRC is highly implicated in immune responses. It can promote T cell proliferation and differentiation, B cell proliferation, participate in T cell and B cell signal transduction pathways, positively regulate antigen receptor-mediated signal transduction pathways and protein kinases, release calcium ions into the cytoplasm, defend against responsive viruses, and regulate the cell cycle [46–48]. ACTN2 is highly expressed in the cytoskeleton and actin filaments and can bind with actin and calcium ions to participate in the formation of muscle structure. Besides, it is a key molecule that maintains the physiological morphology and function of muscles. Down-regulating the expression of ACTN2 may accelerate the loss of vascular smooth muscle function and elasticity. Nevertheless, studies examining the role of these two genes in carotid atherosclerosis are scarce, warranting further exploration [49, 50]. The relationship between ACTC1, LDB3, MYOZ2, TPM2, and CAS remains elusive. The expression levels of ACTC1, LDB3, MYOZ2, and TPM2 were negatively correlated with the infiltration level of most immune cell subtypes, positioning them as potential protective factors against CAS. In addition, while these genes are associated with muscle development and physiological processes, their functions in CAS remain to be elucidated. It is worthwhile recognizing that previous studies have used the same dataset as ours and identified hub genes that, while partially overlapping, are not completely consistent. This may be ascribed to inconsistencies in the algorithms used. For example, Liu et al. identified RBM47, HCK, CD53, TYROBP, and HAVCR2 as hub genes in advanced atherosclerotic plaques via network-based analysis [51]. They first used WGCNA to screen key modules, then constructed protein interaction networks to screen hub genes, all of which were pathogenic genes. Our study initially distinguished the immune phenotypes of the samples using consensus clustering and subsequently screened differentially expressed genes using the maximum neighborhood component algorithm. These hub genes may play an instrumental role in the differentiation of immune phenotypes among samples. Herein, hub genes were screened from two perspectives of high and low immune cell infiltration, including potential pathogenic and protective genes. However, some limitations of our study should not be overlooked. To begin, the screening models for diagnostic genes are diverse and complex, and the diagnostic efficacy of the screened genes remains unknown in other datasets. Thus, high-quality cohorts with sufficient sample sizes are necessary to validate our results. Secondly, regularization techniques and cross-validation were not utilized in the present study. Applying these methods through various machine learning algorithms can enhance the accuracy and reliability of results. Considering the limited number of genes screened using the maximum neighborhood component algorithm, some genes might have been validated by previous studies. Therefore, instead of further narrowing our scope with regularization techniques and cross-validation, the diagnostic efficacy of all unpublished genes in the downloaded datasets was validated. Conclusion The enrichment of immune cells in vascular tissues promoted pathological changes in CAS. Advanced CAS was characterized by high immune cell infiltration levels, whereas early CAS was hallmarked by low immune cell infiltration levels. Moreover, CAS progression may be related to the immune response pathway. Biological processes related to muscle cell development may delay CAS progression. Meanwhile, the expression of the hub genes CAS. PTPRC and ACTN2, ACTC1, LDB3, MYOZ2, and TPM2, identified in the interaction network of differentially expressed genes between cluster A and healthy vascular tissues, play an essential role in regulating the immune microenvironment of CAS and participate in its occurrence and progression. Finally, PTPRC and ACTN2, ACTC1, LDB3, MYOZ2, and TPM2 demonstrated favorable efficacy for distinguishing between high and low immune cell infiltration CAS samples, as well as for differentiating early from advanced CAS stages. 6 Mar 2024 PONE-D-24-01429Screening of potential regulatory genes in carotid atherosclerosis vascular immune microenvironment.PLOS ONE Dear Dr. hou, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Apr 20 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Misbahuddin Rafeeq Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating the following financial disclosure: "This work was supported by Hebei Provincial Administration of Traditional Chinese Medicine Project, No: Z2022004." Please state what role the funders took in the study. If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 3. In the online submission form, you indicated that "The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request." All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. 4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Zhang Y et al., studied potential regulatory genes in carotid atherosclerosis vascular immune microenvironment. Identifying potential genes that regulate the progression of carotid atherosclerosis is a demanding research topic. There is relevant published work so far (Zheng K et al., 2023, Dong R et al., 2022, Wang L et al., 2021). This study further extends the contemporary knowledge in carotid atherosclerosis immunology. Previous studies used same database and identified same hub genes in some extent. For example, Liu C., 2021 identified RBM47, HCK, CD53, TYROBP, and HAVCR2 as Hub Genes using the same Gene Expression Omnibus database (GSE43292). In addition, Yao Yuan et al., 2024 analyzed GSE43292 database and identified hub genes such as AKTIP, ASPN, FAM26E, RAB23, PLS3, and PLSCR4. Ni Jiajun et al., 2023 and Chen M., et al., 2021 were used GSE28829 database and explored Go and KEGG pathways. Therefore, I am unsure how this study is novel compared to what is published so far. Reviewer #2: In this research paper, the authors aim to uncover the changes in the immune microenvironment of vascular tissues at various stages during the progression of carotid atherosclerosis. Additionally, they seek to identify potential hub genes that regulate the immune microenvironment in this pathology. It is an intersting work ; however, I have some comments and minor revisions : 1. This paper is founded on the data from two research papers (related to GSE43292 and GSE28829), which should be cited as references. 2. There is a mistyping in the results section. It should be corrected to "immune score" instead of "immune sore". 3. In the results section, the authors reported that "ACTN2 was positively correlated with most immune cell subtypes infiltration" and "PTPRC was negatively correlated with most immune cell subtypes infiltration." However, the discussion section contradicts these findings, stating that "ACTN2 is negatively correlated with most immune cell subtypes infiltration" and "PTPRC is positively correlated with most immune cell subtypes infiltration." To ensure consistency and coherence, the sentence should be corrected to align with the results and discussion. 4. In Figure 1C, “CAP” should be replaced by “CAS”. 5. The legend of Figure 1B and 2B should be corrected as follows: "The differences in immune score between the carotid atherosclerosis and control samples." 6. In the legend of Figure 5A and 5C, abbreviations such as BP (Biological Process) and CC (Cellular Component) should be added. 7. In the legend of Figures 5E and 5F, the significance of colors should be specified. 8. Genes such as ACTN2 and PTPRC should be written in italics. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Md Mamun Al Amin, Ph.D. Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. Submitted filename: PONE-D-24-01429_Review-comments_Mamun_20240217.docx 3 May 2024 Reviewer #1: Zhang Y et al., studied potential regulatory genes in carotid atherosclerosis vascular immune microenvironment. Identifying potential genes that regulate the progression of carotid atherosclerosis is a demanding research topic. There is relevant published work so far (Zheng K et al., 2023, Dong R et al., 2022, Wang L et al., 2021). This study further extends the contemporary knowledge in carotid atherosclerosis immunology. Previous studies used same database and identified same hub genes in some extent. For example, Liu C., 2021 identified RBM47, HCK, CD53, TYROBP, and HAVCR2 as Hub Genes using the same Gene Expression Omnibus database (GSE43292). In addition, Yao Yuan et al., 2024 analyzed GSE43292 database and identified hub genes such as AKTIP, ASPN, FAM26E, RAB23, PLS3, and PLSCR4. Ni Jiajun et al., 2023 and Chen M., et al., 2021 were used GSE28829 database and explored Go and KEGG pathways. Therefore, I am unsure how this study is novel compared to what is published so far. Re: Thank you very much for your comments, we understand your concern. First, we added the expression of some hub genes in the carotid atherosclerosis and their correlation with immune cells.These hub genes are completely new, and no previous studies have focused on their role in the carotid atherosclerosis. Secondly, we started to screen the key genes from the immune microenvironment.We have strengthened the correlation between hub genes and the immune microenvironment and disease progression.It's one of our highlights.Thank you very much again for your comments, we benefit from your comments. Reviewer #2: In this research paper, the authors aim to uncover the changes in the immune microenvironment of vascular tissues at various stages during the progression of carotid atherosclerosis. Additionally, they seek to identify potential hub genes that regulate the immune microenvironment in this pathology. It is an intersting work ; however, I have some comments and minor revisions : 1. This paper is founded on the data from two research papers (related to GSE43292 and GSE28829), which should be cited as references. Re: Thank you very much for your comments, we have cited the above two research papers. 2. There is a mistyping in the results section. It should be corrected to "immune score" instead of "immune sore". Re: Thank you very much for your comments, we apologize for such an error, we have changed. 3. In the results section, the authors reported that "ACTN2 was positively correlated with most immune cell subtypes infiltration" and "PTPRC was negatively correlated with most immune cell subtypes infiltration." However, the discussion section contradicts these findings, stating that "ACTN2 is negatively correlated with most immune cell subtypes infiltration" and "PTPRC is positively correlated with most immune cell subtypes infiltration." To ensure consistency and coherence, the sentence should be corrected to align with the results and discussion. Re: Thanks for your comments, we have made changes. ACTN2 was negatively correlated with most immune cell subtypes infiltration and PTPRC was positively correlated with most immune cell subtypes infiltration. 4. In Figure 1C, “CAP” should be replaced by “CAS”. Re: Thank you very much for your comments. We have revised and replaced Figure1 in the manuscript. 5. The legend of Figure 1B and 2B should be corrected as follows: "The differences in immune score between the carotid atherosclerosis and control samples." Re: Thank you very much for your comments, we have made changes. 6. In the legend of Figure 5A and 5C, abbreviations such as BP (Biological Process) and CC (Cellular Component) should be added. Re: Thank you very much for your comments, we have added the full names of BP (Biological Process), CC(Cellular Component) and MF (molecular function). 7. In the legend of Figures 5E and 5F, the significance of colors should be specified. Re: Thank you very much for your comments, we have revised it. Red to yellow indicated that genes rank from high to low in the interaction network. 8. Genes such as ACTN2 and PTPRC should be written in italics. Re: Thank you very much for your comments, we have revised it. Submitted filename: Response to Reviewers.docx 14 Jun 2024 PONE-D-24-01429R1Screening of potential regulatory genes in carotid atherosclerosis vascular immune microenvironment.PLOS ONE Dear Dr. hou, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 29 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Misbahuddin Rafeeq Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: I Don't Know ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: No ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: In the revised version, Zhang and colleagues have included three additional figures (Figure 9, 10 and 11). I am wondering, the authors have validated diagnostic efficiency on those two GSE cohorts. Models developed to identify diagnostic genes may be overly complex and tailored to the specific dataset, leading to poor performance when applied to new, unseen data. Regularization techniques and cross-validation are necessary to mitigate this type of risk. Despite this limitation, the authors have reported novel hub gene that may have a significant impact in the field. Reviewer #2: Thank you for addressing all my concerns, however, the manuscript still needs to be revised: 1. First, there are several spelling and grammar errors, so the English must be proofread by a native English speaker. 2. There is a mistyping in the manuscript. It should be corrected to "GSE 28829" instead of "GSE 288292". 3. As suggested by the reviewer, previous studies used the same database and identified some hub genes, such as RBM47, HCK, CD53, AKTIP, ASPN, PLS3, and PLSCR4. In this regard, the results of these papers should be discussed in the manuscript to compare them with the present study and to suggest hypotheses that could explain the differences in hub genes found in these different studies. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. 9 Jul 2024 Reviewer #1: In the revised version, Zhang and colleagues have included three additional figures (Figure 9, 10 and 11). I am wondering, the authors have validated diagnostic efficiency on those two GSE cohorts. Models developed to identify diagnostic genes may be overly complex and tailored to the specific dataset, leading to poor performance when applied to new, unseen data. Regularization techniques and cross-validation are necessary to mitigate this type of risk. Despite this limitation, the authors have reported novel hub gene that may have a significant impact in the field. Reply: Thank you very much for your review of our manuscript and your valuable comments. We have learned much from your comments, revised the manuscript, and improved the quality of the manuscript. We agree with you. We verified the diagnostic efficacy in both the GSE43292 cohort (Figure 9) and the GSE28829 cohort (Figure 10). However, as you are concerned, the screening models for diagnostic genes are diverse and complex, and the diagnostic efficacy of the genes we screened is unknown in other datasets. This still requires high-quality cohorts with sufficient sample sizes to validate our results. We did not use regularization techniques and cross-validation. A variety of machine learning algorithms, including regularization techniques and cross-validation, screen key genes and intersect them, which can improve the accuracy and reliability of results. Considering that the number of genes screened by the maximum neighborhood component algorithm is limited, and some genes have been confirmed by previous studies. Therefore, instead of further narrowing the scope by regularization techniques and cross-validation, we directly validated the diagnostic efficacy of all unpublished genes in the data sets. The above shortcomings were supplemented in our discussion. Thank you again for your comments, we have learned a lot from them. Reviewer #2: Thank you for addressing all my concerns, however, the manuscript still needs to be revised: 1.First, there are several spelling and grammar errors, so the English must be proofread by a native English speaker. Reply: Thank you for your comments, we have asked a native English speakers to polish our manuscript. 2.There is a mistyping in the manuscript. It should be corrected to "GSE 28829" instead of "GSE288292". Reply: Thank you for your comments. We apologize for the error. We have made changes in the manuscript. 3.As suggested by the reviewer, previous studies used the same database and identified some hub genes, such as RBM47, HCK, CD53, AKTIP, ASPN, PLS3, and PLSCR4. In this regard, the results of these papers should be discussed in the manuscript to compare them with the present study and to suggest hypotheses that could explain the differences in hub genes found in these different studies. Reply: Thank you very much for your comments. We have benefited from your comments. We elaborated on this in our discussion. Previous studies used the same data sets as ours. These studies, including ours, have obtained hub genes that, while partially overlapping, are not completely consistent. This may be related to the inconsistency of the algorithms used. Liu et al. (33519905) identified RBM47, HCK, CD53, TYROBP, and HAVCR2 as Hub Genes in Advanced Atherosclerotic Plaques via Network-Based Analysis. They first used WGCNA to screen key modules, then constructed protein interaction networks and screened out hub genes, all of which were pathogenic genes. Our study first distinguished the immune phenotypes of the samples using consensus clustering. On this basis, differentially expressed genes were screened, and hub genes were screened by maximum neighborhood component algorithm. These hub genes may play an important role in the immune phenotype differentiation of samples. In our study, hub genes were screened from two perspectives of high and low immune cell infiltration, including potential pathogenic and protective genes. Thank you again for your comments, we have benefited from them and have improved the quality of our manuscripts accordingly. Submitted filename: Response to Reviewers.docx 15 Jul 2024 Screening of potential regulatory genes in carotid atherosclerosis vascular immune microenvironment. PONE-D-24-01429R2 Dear Dr. xianming hou, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Misbahuddin Rafeeq Academic Editor PLOS ONE 2 Sep 2024 PONE-D-24-01429R2 PLOS ONE Dear Dr. hou, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Misbahuddin Rafeeq Academic Editor PLOS ONE